Stock comparison
JOHNSON & JOHNSON is 313.1x more valuable than Amylyx Pharmaceuticals, Inc. by market capitalization ($618.61 B vs $1.98 B). Compare market value, revenue, profit, margins, filings, and source pages in one place.
Quick answer
JNJ is larger
JOHNSON & JOHNSON is 313.1x more valuable than Amylyx Pharmaceuticals, Inc. by market capitalization ($618.61 B vs $1.98 B).
Market value leader
JNJ
JOHNSON & JOHNSON is 313.1x more valuable than Amylyx Pharmaceuticals, Inc. by market capitalization ($618.61 B vs $1.98 B).
Revenue leader
JNJ
AMLX: $0.00 vs JNJ: $94.19B.
Profit leader
JNJ
AMLX: -$144.74M vs JNJ: $26.80B.
| Metric | AMLX | JNJ |
|---|---|---|
| Market cap | $1.98 B | $618.61 B |
| US-listed rank | #2137 | #18 |
| Revenue (latest FY) | $0.00 | $94.19B |
| Net income (latest FY) | -$144.74M | $26.80B |
| Net margin | - | 28.5% |
| P/E (trailing FY) | - | 23.1x |
| SEC filings | 403 | 990 |
Jump from this comparison into the underlying pages for market value, annual fundamentals, and company filing history.
Market cap uses refreshed market data. Revenue, net income, margins, and trailing fiscal-year P/E use annual company facts from filings. If a metric is missing, the source data did not have a clean recent annual value for that company.
JOHNSON & JOHNSON is 313.1x more valuable than Amylyx Pharmaceuticals, Inc. by market capitalization ($618.61 B vs $1.98 B).
In their latest fiscal years, Amylyx Pharmaceuticals, Inc. reported $0.00 in revenue while JOHNSON & JOHNSON reported $94.19B.
Full pages: Amylyx Pharmaceuticals, Inc. and JOHNSON & JOHNSON, or browse the full rankings.